Advanced Filters
noise

Hematologic Cancer Clinical Trials

A listing of Hematologic Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 329 clinical trials
S Site Contact

A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological Malignancies

Evaluate the Safety, Pharmacokinetics and Efficacy of CHT101 in Subjects With Relapsed or Refractory T or B Cell Hematological Malignancies

18 - 70 years of age All Phase 1
H He Huang, MD

A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

A study of CTA101 UCAR-T cell injection in patients with relapsed or refractory CD19+ B-line hematological malignancy

3 - 70 years of age All Phase N/A
K Kathleen Ji

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

Reduced intensity conditioning (RIC) has been increasingly adopted as a modality to allow preparative conditioning pre-transplant to be tolerated by older adults or those patients that are otherwise unfit for myeloablative conditioning. In this study Reduced intensity conditioning (RIC) conditioning is used and followed by match aploidentical donor peripheral blood …

18 - 75 years of age All Phase 1
Y Yuqin Song, Doctor

A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies

Evaluation of the safety, tolerability, pharmacokinetics, and preliminary efficacy of XS-04 in patients with relapsed or refractory hematologic malignancies

18 - 75 years of age All Phase 1
R Richard Lin, MD, PhD

Cord Blood Transplant in Adults With Blood Cancers

Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and total body irradiation therapy) given to prepare the body …

21 - 65 years of age All Phase 2

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.

18 years of age All Phase 1
D Dong Chen

Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies

The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with relapsed/refractory hematological malignancies.

18 - 75 years of age All Phase 1
C Cancer Connect

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

This phase I trial studies the safety of transplantation with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells in conjunction with the immunomodulating drug, Zoledronate, given in the post-transplant period to treat pediatric patients with relapsed or refractory hematologic malignancies or high risk …

7 - 21 years of age All Phase 1
V Vanessa Lopez-Ozuna, MD, PhD

CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies

The investigators propose an early phase study defined as a phase I/II trial assessing safety, feasibility and efficacy of CLIC-1901 autologous anti-CD19 Chimeric Antigen Receptor T cells (CAR-T) cells for participants with relapsed/refractory CD19 positive (CD19+) Acute Lymphoblastic Leukemia (ALL) and non-Hodgkin's Lymphoma (NHL). The Initial Stage of the study …

18 - 75 years of age All Phase 1/2
Y Ying Cheng, Bachelor

Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of CM369 in Advanced Solid Tumors & Hematologic Malignancies

This is a nonrandomized, open-label, multicenter, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of CM369 in subjects with advanced solid tumors and Hematologic Malignancies.

18 - 75 years of age All Phase 1

Simplify language using AI